Table 4.

Acute rejection rate in Lamivudine and Tenofovir groups during the follow-up period

	Acute rejection (n, %) 1 month	Acute rejection (n, %) 6 months	Acute rejection (n, %) 12 months	Acute rejection (n, %) >12 months
Lamivudine group	5 (5.3%)	2 (2.6%)	4 (6.4%)	1 (1.8%)
Tenofovir group	18 (8.6%)	6 (2.9 %)	7 (3.7%)	3 (1.6%)
P. value	0.32	1*	0.47*	1*

* Fisher’s Exact Test